Originally published In Press as doi:10.1074/jbc.M111872200 on March 23, 2002
J. Biol. Chem., Vol. 277, Issue 23, 21050-21060, June 7, 2002
Phosphorylation of Varicella-Zoster Virus IE63 Protein by
Casein Kinases Influences Its Cellular Localization and Gene Regulation
Activity*
Sébastien
Bontems
,
Emmanuel
Di Valentin§,
Laurence
Baudoux,
Bernard
Rentier,
Catherine
Sadzot-Delvaux, and
Jacques
Piette¶
From the Laboratory of Virology and Immunology, University of
Liège, B-4000 Liège, Belgium
Received for publication, December 13, 2001, and in revised form, March 20, 2002
 |
ABSTRACT |
During the early phase of varicella-zoster virus
(VZV) infection, Immediate Early protein 63 (IE63) is expressed rapidly
and abundantly in the nucleus, while during latency, this protein is
confined mostly to the cytoplasm. Because phosphorylation is known to
regulate many cellular events, we investigated the importance of this
modification on the cellular localization of IE63 and on its regulatory
properties. We demonstrate here that cellular casein kinases I and II
are implicated in the in vitro and in vivo
phosphorylation of IE63. A mutational approach also indicated that
phosphorylation of the protein is important for its correct cellular
localization in a cell type-dependent fashion. Using an
activity test, we demonstrated that IE63 was able to repress the gene
expression driven by two VZV promoters and that phosphorylation of the
protein was required for its full repressive properties. Finally, we
showed that IE63 was capable of exerting its repressive activity in the
cytoplasm, as well as in the nucleus, suggesting a regulation at the
transcriptional and/or post-transcriptional level.
 |
INTRODUCTION |
The varicella-zoster virus
(VZV)1 is a neurotropic virus
belonging to the Alphaherpesvirinae subfamily and responsible for two
distinct diseases as follows: chicken pox, an illness affecting mostly
young children, and shingles, resulting from the virus reactivation in
elderly and immunocompromised people (1). Indeed, the characteristics
of all members of this viral subfamily are their ability to establish
latency in sensory ganglia after primary infection and to reactivate
decades later. Molecular events leading to the establishment and
maintenance of the virus latency, as well as to its reactivation, are
still poorly understood. It appears to be the result of a delicate
balance between cellular factors, viral proteins and the host immune
system (2). In lytically infected cells, the expression of VZV genes
seems to occur in cascade-like events, previously described for herpes
simplex virus type 1 (HSV-1) (3). Immediate early (IE) gene-encoded
proteins are the first ones to be active because they act as regulators on their own expression, as well as on the transcriptional activation of early (E) and late (L) genes. Among the immediate early proteins, IE62 seems to be the major regulating factor with regard to its transactivation properties on all classes of viral genes (4-8).
Transcripts from several VZV open reading frames (ORFs 4, 21, 29, 62, and 63) have been detected in latently infected human ganglia (9-15).
Moreover, several of the corresponding proteins have been detected in
latently infected cells (16-18). During latency, the expression of
viral proteins also present during the lytic phase of infection is an
original feature that VZV does not share with HSV-1. IE63 was the first
protein described in a latency context, first in an animal model (19)
and second in human tissue sections (16-18). This 45-kDa
phosphoprotein, encoded by two identical ORFs (ORF63 and ORF70), is
present in the virion tegument (19). IE63 is abundantly produced during
the early phase of infection (20) and is essential for VZV replication
(21). Its activity as a potential transcription factor remains unclear.
IE63 has been shown to exert positive or negative effects on gene
transcription, depending on the type of promoter studied (22). However,
others claimed that IE63 played only a minor role in the control of VZV gene expression (23). An interesting feature of the VZV IE63 protein is
its cellular localization during the different stages of the viral
cycle. Indeed, in the early phase of infection, IE63 is predominantly
present in the nucleus of infected cells (20). On the other hand, IE63
exhibits an exclusive cytoplasmic localization during latency and can
be found both in the nucleus and the cytoplasm when reactivation occurs
(17). The presence of IE63 and its localization modification might
reflect an important role in the latency process. Phosphorylation and
dephosphorylation events are known to be usually involved in regulation
mechanisms such as nuclear and cytoplasmic translocation, for example.
In vitro phosphorylation of IE63 may be achieved using
recombinant casein kinase II (CKII), and the protein is also
phosphorylated in VZV-transfected Mewo cells (24). The phosphorylation
sites used in these in vivo and in vitro assays
are located predominantly at the carboxyl-terminal region of the
protein. Recently, it has also been shown that IE63 is a substrate for
ORF47, one of the VZV-encoded kinases (25). Indeed, using stringent
in vitro conditions, an extensive phosphorylation of the
protein is catalyzed by the ORF47-encoded kinase, which can compete
with CKII for the binding to IE63. This viral serine/threonine kinase
has often been compared with CKII, notably because they may both use
ATP or GTP as phosphate donor (26). These results demonstrate that
viral and cellular kinases are capable of phosphorylating IE63.
The purpose of this paper was to analyze in further detail the IE63
phosphorylation status. For this, we used a mutational approach to
investigate the importance of some of the putative phosphorylation
sites on the cellular localization of IE63 and on its activity. Ten
potential phosphorylation sites for casein kinase I (CKI), CKII, and
protein kinase C (PKC) or Cdc2 were mutated, and in vitro
kinase assays were carried out using these mutated proteins as
substrates. Results indicated that these sites are important in the
phosphorylation process of IE63, using either recombinant CKI and CKII
or protein extracts from Vero (non-neuronal) or ND7 (neuronal) cells.
Immunofluorescent studies on these neuronal and non-neuronal cell lines
transfected with the mutated IE63 proteins indicated that
phosphorylation on these residues is required for a suitable cellular
localization of the protein in Vero but not in ND7 cells. We also
demonstrated that wild-type IE63 protein possesses some repressive
properties on two VZV promoters (DNA polymerase and thymidine kinase)
and that mutation of the phosphorylation sites strongly impaired its
activity. Finally, we also witnessed evidence of an important feature
of this protein: IE63 is able to exert its repressive activity both in
the nucleus and in the cytoplasm of transfected cells, suggesting that
IE63 acts through a transcriptional or post-transcriptional mechanism
in the nucleus and/or through a post-transcriptional mechanism in the
cytoplasm of transfected cells.
 |
EXPERIMENTAL PROCEDURES |
Plasmids--
The wild-type IE63 gene was amplified
by PCR from the pGEX-63 (20) and cloned in the pcDNA3.1
vector (Invitrogen) to generate the pcDNA63 wt. We also constructed
the pcDNA63inv, where the IE63 gene was cloned in the
reverse orientation. This plasmid is used as negative control in some
experiments. Mutations were introduced into the IE63 gene by
PCR using the site-directed mutagenesis kit system (Stratagene). For
this, several sets of primers were synthesized (Eurogentec). Table I
summarizes the strategy used. All mutated genes were cloned in the
pGEX-5x (Amersham Biosciences) and transformed in Escherichia
coli JM109 strain in order to produce GST fusion proteins. All
constructions were subsequently sequenced to verify that no additional
mutations were introduced during PCR.
To generate pcDNA-63
K, the carboxyl-terminal region of IE63
(from amino acids 210-278) was removed by digestion of pcDNA63 wt
with KpnI and self-ligation. The putative nuclear
localization signal (NLS), from amino acids 260-263, was removed by
digesting pcDNA63 vector at ClaI sites (previously added
by PCR) and self-ligation in order to generate pcDNA-63
NLS. A
plasmid (pPol-luc), where the luciferase reporter gene was under the
control of the VZV DNA polymerase gene promoter (pPol), was constructed
by inserting a 404-bp-long fragment encompassing the pPol promoter into
the pGL3-Basic vector (Promega). This fragment was the result of an HindIII digestion of the pPol-CAT plasmid (28). ORF62 was
also cloned in pcDNA3.1
to generate pcDNA-62.
pTkCAT-L, where the VZV thymidine kinase promoter controls the
expression of the chloramphenicol acetyltransferase (CAT) reporter
gene, has been described previously (28).
Cells, Virus, and Infection Study--
Vero cells (a monkey
kidney cell line, ATCC CCL-81) were grown in M199 medium (Invitrogen)
supplemented with 10% fetal bovine serum (Invitrogen). ND7 cells
(ECACC number 92090903) (a gift from Dr. D. Latchman, University
College London Medical School) are the result of the fusion of murine
neuroblastoma cells with primary nerve cells from rat dorsal root
ganglia (27). They were grown in RPMI 1640 (BioWhittaker) supplemented
with 5% fetal bovine serum (Invitrogen). Cell-free virus was prepared
from VZV-infected Mewo cells, as described previously (29). Briefly,
VZV-infected Mewo cells were collected by scraping and resuspended in 1 ml of PGSA buffer supplemented with 10% fetal calf serum (29). Cells were mixed with 1 ml of glass beads (1 mm in diameter) and subjected to mechanical shaking in a mini-BeadBeater (Biospec Products,
Bartlesville, OK), at low speed for 10 s. Supernatant containing
the cell-free virus was collected by several centrifugations. 150 µl
of supernatant was added to Vero and ND7 cells previously grown on
coverslides into 10-mm dishes and then supplemented with fresh medium.
Cells were fixed at 24, 48, and 72 h post-infection with a
solution of acetone/methanol (v/v) for 20 min at
20 °C. After
fixation, the nonspecific sites were saturated with a milk-blocking solution (15% in PBS) and then incubated with a monoclonal antibody directed against IE63 (18). The secondary antibody used was coupled
with fluorescein isothiocyanate (FITC) (Dako), and cells previously
counterstained with a 1% (v/v) Evans Blue solution were observed by
fluorescent microscopy (Nikon).
Total Cellular Protein Extracts--
Total cellular extracts
from Vero and ND7 cells were obtained by RIPA lysis. Briefly, cells
from three confluent 80-cm2 dishes were harvested, washed
in cold PBS (137 mM NaCl, 8 mM Na2HPO4, 1.5 mM
KH2PO4, 2.7 mM KCl, pH 7.4), and
resuspended in 1 ml of RIPA lysis buffer (PBS supplemented with 1%
Nonidet P-40, 0.5% Tween 20, 0.1% (w/v) SDS, 5 mM EDTA, 1 mM dithiothreitol, and protease inhibitors (Complete
Protease Inhibitors, Roche Molecular Biochemicals)). Cells were allowed
to swell on ice for 30 min, vortexed, then transferred on ice for an
additional 30 min, and centrifuged 20 min at 20,000 × g at 4 °C. Supernatants were kept at
80 °C.
Nuclear and Cytoplasmic Protein Extracts--
Cells from three
confluent 80-cm2 dishes were harvested, washed in cold PBS,
pelleted, and resuspended in 1.2 ml of cold hypotonic buffer (10 mM HEPES-KOH, pH 7.9, 2 mM MgCl2,
0.1 mM EDTA, 10 mM KCl, 1 mM
dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, and
protease inhibitors (Complete Protease Inhibitors, Roche Molecular Biochemicals)). Pellets were allowed to swell on ice for 10 min. After
addition of 0.5% (v/v) Nonidet P-40, cells were vortexed for 2 or
3 s. Suspension was then centrifuged at 20,000 × g for 30 s; the supernatant containing the cytoplasmic
fraction was kept at
80 °C, and the pellet of nuclei was
resuspended in 50 µl of cold saline buffer (50 mM
HEPES-KOH, pH 7.9, 2 mM MgCl2, 0.1 mM EDTA, 50 mM KCl, 400 mM NaCl,
10% (v/v) glycerol and protease inhibitors (Complete Protease
Inhibitors, Roche Molecular Biochemicals)). Cells were allowed to swell
on ice for 30 min. After centrifugation (15 min at 20,000 × g at 4 °C), the supernatant containing the nuclear
proteins was stored at
80 °C.
For all in vitro kinase assays, protein extracts were
dialyzed with a high volume (up to 2 liter) of casein kinase II buffer (50 mM Tris-HCl, pH 7.4, 140 mM KCl, and 10 mM MgCl2) for 2 h. Protein concentrations
were measured by the Bradford method (Bio-Rad).
Immunoprecipitations--
CKI and CKII were immunoprecipitated
from Vero and ND7 cellular extracts using polyclonal antibodies raised
against CKI
(R-19: sc-6474, from Santa Cruz Biotechnology, Inc.) and
CKII
(C-18: sc-6479, from Santa Cruz Biotechnology, Inc.),
respectively. 40 µl of protein A-Sepharose (Amersham Biosciences)
were incubated overnight at 4 °C with 5 µl of antibodies and
several concentrations of cellular extracts in the immunoprecipitation
buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl,
0.5% Nonidet P-40, Complete Protease Inhibitors, Roche Molecular
Biochemicals) that includes a mixture of phosphatase inhibitors (1 mM Na3VO4, 0.5 mM
phenylmethylsulfonyl fluoride, 1 mM NaF, 0.5 mM
-glycerophosphate). The resin was then washed 3 times with cold CKII buffer.
In Vitro Kinase Assays--
GST-63 wt protein was expressed from
the pGex3X-ORF-63 vector and purified on glutathione-Sepharose 4B
(Amersham Biosciences) as described previously (20). Mutant GST-63
proteins were expressed and purified according to the same protocol.
GST-I
B
protein was used as positive control and produced as
described previously (30). In vitro kinase assays were
performed with cellular extracts, recombinant kinases, or
immunoprecipitated kinases. Several concentrations of cellular extracts
or recombinant kinases were added to 20 µl of glutathione-Sepharose
4B-bounded GST-63 protein and with 10 µCi of
[
32P]ATP (ICN). For the assays using the
immunoprecipitated kinases, 10 µCi of [
32P]ATP
(ICN) and 2 µg of GST-63 (eluted from the resin using 10 mM GSH in 50 mM Tris-HCl, pH 8) were added to
resin-bound kinases. All reactions were performed in CKII buffer,
supplemented with the protease and phosphatase inhibitors mixtures, for
30 min at 30 °C. Resins were washed 3 times with CKII buffer. The
samples were loaded on a 10% SDS-PAGE gel. After migration, the gel
was dried and autoradiographed on a Fuji x-ray film (General
Electrics). Quantifications were carried out by PhosphorImaging
(Molecular Dynamics).
For some in vitro kinase assays,
5,6-dichloro-1-
-D-ribofuranosylbenzimidazole (DRB)
(ICN), which is an inhibitor of casein kinases, was used at several concentrations.
Transient Transfection Studies--
Transfection studies were
carried out with cells (Vero or ND7) seeded into 35-mm diameter 6-well
cluster dishes using the FuGENE 6 transfectant reagent according to the
manufacturer's prescriptions (Roche Molecular Biochemicals). In these
experiments, pPol-luc or pTkCAT-L was used as reporter vectors and
pcDNA 3.1
, pcDNA62, pcDNA63 wt, pcDNA63-5M,
pcDNA63-10M, pcDNA-63
NLS, pcDNA-63
K as expression
vectors under the control of cytomegalovirus promoter. The amounts of
DNA were adjusted with herring sperm DNA. Special attention was made to
obtain an equimolar ratio of cytomegalovirus promoters in each
independent experiment. Luciferase assays were performed using the
"Luciferase Reporter Gene Assay, High Sensitivity" kit (Roche
Molecular Biochemicals), according to the instructions of the
manufacturer. For each experiment, the concentration of proteins in
each sample was measured in order to normalize the results. Data from
luciferase and CAT assays were collected from at least four independent
transfection experiments. CAT activity assays were performed as
described previously (28). For Western blot analysis, 15 µg of
protein extracts of ND7-transfected cells were loaded on a 10%
SDS-PAGE gel. After migration and transfer, detection of IE63 was
performed using a monoclonal antibody 9A12, as described previously
(18), or a polyclonal antibody (20).
Immunofluorescent Studies--
Vero and ND7 cells were grown on
coverslides into 10-mm dishes and transfected with 1 µg of
pcDNA63 wt or mutated forms using 3 µl of FuGENE 6 reagent (Roche
Molecular Biochemicals). 48 h post-transfection, the cells were
fixed with a solution of acetone/methanol (v/v) during 20 min at
20 °C. After fixation, the nonspecific sites were saturated with a
milk-blocking solution (15% in PBS) and then incubated with antibodies
directed against IE63. In these experiments, a rabbit polyclonal
anti-IE63 serum (20) or a monoclonal antibody directed against IE63
(18) were used. Anti-rabbit or anti-mouse secondary antibodies coupled
with fluorescein isothiocyanate (FITC) (Dako) were then used, and the
cells, previously counterstained with a 1% (v/v) Evans Blue solution,
were observed by fluorescent microscopy (Nikon).
 |
RESULTS |
Identification and Mutation of the Putative Phosphorylation Sites
in the Carboxyl-terminal Region of IE63---
Previous studies
suggested that important phosphorylation sites are located in the
carboxyl-terminal region (amino-acids 142-278) of the IE63 protein
(24). Therefore, we decided to focus our work on this part of the IE63
protein. A computer analysis was carried out to identify putative
phosphorylation sites for cellular kinases in the carboxyl-terminal
region of IE63. For this, we used the PhosphoBase prediction tool
software available on the Center for Biological Sequence Analysis web
site (31). As shown in Fig. 1, the
analysis revealed the presence of 10 potential phosphorylatable serine
or threonine residues in this region. Five of them (Ser-150, Ser-165,
Ser-181, Ser-186, and Thr-171) are potential targets for CKII and four
others (Ser-173, Ser-185, Thr-201, and Thr-244) for CKI. The Ser-224
was found to be a putative site for PKC and/or p34cdc2-mediated
phosphorylation.

View larger version (58K):
[in this window]
[in a new window]
|
Fig. 1.
Complete DNA sequence of the VZV
IE63 gene and the predicted amino acid sequence.
The putative phosphorylation sites for PKC and/or p34cdc2 (in
green), CKI (in blue), and CKII (in
red) are shown. The bold and
underlined sequence represents the putative NLS.
|
|
In order to assay the importance of these residues in IE63
phosphorylation, we decided to substitute them by alanine residues. The
IE63 gene was cloned first in the pcDNA3.1
expression
vector (Invitrogen) to generate wild-type pcDNA63. We then used a
PCR-based mutagenesis strategy to generate mutants. Resulting plasmids
are listed in Table I. For example, in
pcDNA63-5M, only the five potential phosphorylation sites for CKII
were mutated, whereas in pcDNA63
10M, all 10 potential sites for
CKI, CKII, and PKC/Cdc2-mediated phosphorylation were mutated (Table
I).
View this table:
[in this window]
[in a new window]
|
Table I
List of primers and target plasmids used for the construction of the
IE63 mutants
The 1st column indicates the plasmids generated, and the 2nd column
describes the position of mutated residues in the IE63 gene.
All mutations were introduced by PCR. The 3rd column resumes plasmids
used as target for the PCR strategy, and the primers used are listed in
the last column. Boldface letters represent the mutations introduced.
|
|
In Vitro Kinase Assays Using Recombinant CKI and CKII--
The
mutated IE63-encoding genes were cloned in pGEX-5x
vector (Amersham Biosciences) to generate GST fusion proteins. The expression of the purified fusion proteins was verified by Coomassie Blue-stained SDS-PAGE gel (Fig. 2,
A and B) and Western blotting analysis (data not
shown). In order to improve the impact of the mutations on the
phosphorylation rate of the protein, in vitro kinase assays
were carried out using recombinant CKI and CKII on
GST-63-Sepharose-bound proteins. Phosphorylation of wild-type IE63 was
observed using increasing concentrations of both CKI and CKII (from
10-50 units) (Fig. 2, A and B). Mutation of the five putative phosphorylation sites for CKII (GST-IE63-5M) led to a
slight decrease of the in vitro CKII phosphorylation rate, while, surprisingly, the IE63 phosphorylation rate observed using CKI
was somewhat increased. In vitro phosphorylation of the
GST-63-10M protein, where 10 putative phosphorylation sites for CKI and
CKII were mutated into alanine residues, showed an important decrease of the phosphorylation rate for both kinases. These results indicated that the residues aimed in our study are important for the in vitro IE63 phosphorylation by CKI and CKII. It also suggested that
a few phosphorylation sites for both kinases might still be present
elsewhere in the protein because the mutation of the 10 residues did
not totally abolish the phosphorylation rate of IE63.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
In vitro phosphorylation of
wild-type GST-IE63, GST-IE63-5M, and GST-IE63-10M proteins using
recombinant kinases. 10, 25, and 50 units (U) of CKI
(A) or CKII (B) were used to phosphorylate
(kinase assay, KA) either wild-type GST-63, GST-63-5M, or
GST-63-10M coupled with Sepharose beads with
[ 32P]ATP. After extensive washes and SDS buffer
treatment, all samples were loaded on a 10% SDS-PAGE gel, and an
autoradiography was performed. Coomassie Blue-stained SDS-PAGE gel
(CB) of the kinase assays is shown as loading control.
|
|
In Vitro Kinase Assays Using Cellular Extracts--
To determine
whether cellular kinases were able to phosphorylate the IE63 protein,
we carried out kinase assays using cellular protein extracts. An
in vitro kinase assay was then performed on wild-type
GST-IE63 using 50 µg of total, cytoplasmic, or nuclear protein
extracts from Vero cells previously dialyzed against CKII buffer (Fig.
3A). In this experiment
GST-I
B
protein was used as a positive control because its
CKII-mediated phosphorylation was described by several authors (30,
32). An intense phosphorylation of wild-type GST-IE63 using total,
cytoplasmic, or nuclear protein extracts from Vero cells was observed.
This phosphorylation was strongly reduced when reaction was performed
in the presence of 2 mM DRB, an inhibitor of both CKI and
CKII (33). This experiment allowed us to conclude that extracts from
Vero cells contain casein kinase activities almost equally present in
the nucleus and the cytoplasm. In order to confirm the presence and the
activity of these kinases in cellular extracts, CKI and CKII were
immunoprecipitated from cytoplasmic and nuclear protein extracts from
Vero cells, and in vitro kinase assays were performed (Fig.
3B). A phosphorylation of IE63 was observed with
immunoprecipitated CKI and CKII either from the nucleus or cytoplasm of
Vero cells, reinforcing our in vitro observations that both
cellular CKI and CKII are capable of phosphorylating IE63.

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 3.
In vitro phosphorylation of
wild-type GST-IE63 using protein extracts from Vero cells, in the
presence (+) or absence ( ) of DRB (A) or using
immunoprecipitated CKI or CKII from Vero cells protein extracts
(B). A, GST, wild-type GST-IE63, or GST-I B
coupled with Sepharose beads were incubated with 50 µg of total,
cytoplasmic, or nuclear protein extracts from Vero cells, previously
dialyzed in CKII buffer, or with 200 units of CKII in the presence of
[ 32P]ATP. DRB, an inhibitor of CK I and II, was also
used in this experiment at a final concentration of 2 mM.
B, CKI and CKII were immunoprecipitated from Vero cells
protein extracts and incubated with 2 µg of previously eluted
wild-type GST-63 in the presence of [ 32P]ATP. After
extensive washes and SDS buffer treatment, all samples were loaded on a
10% SDS-PAGE gel and autoradiographed.
|
|
We then decided to compare the relative phosphorylation rate of
wild-type GST-IE63 in two different cell lines: Vero cells, which are
non-neuronal and permissive cells, and ND7 cells, a neuronal cell line
described previously (26) as non-permissive to HSV-1 infection. First,
we investigated whether or not ND7 was also non-permissive to VZV
infection. For this, Vero and ND7 cells were infected with cell-free
virus for 24, 48, and 72 h. An immunofluorescence analysis was
then carried out using an anti-IE63 monoclonal antibody. At 48 h
post-infection, a few IE63-positive foci were observed in Vero cells,
and their numbers largely increased 72 h post-infection (Fig.
4). At identical time points, neither IE63 expression nor cytopathic effect can be detected on ND7 cells, suggesting that this cell line is non-permissive to VZV infection.

View larger version (124K):
[in this window]
[in a new window]
|
Fig. 4.
Infection of Vero and ND7 cells with a
cell-free VZV preparation. Vero and ND7 cells were grown on
coverslides and then infected with cell-free VZV. Cells were fixed at
24, 48, and 72 h post-transfection. Immunostaining analysis was
carried out using a monoclonal antibody (9A12) directed against IE63.
Secondary antibody used was coupled with FITC.
|
|
In vitro kinase assays using total protein extracts from
both cell lines were then carried out in the presence or in the absence of DRB. PhosphorImaging and Coomassie Blue-stained SDS-PAGE gel densitometry analyses were used to determine the relative
phosphorylation rate of the IE63 protein (Fig.
5). From several independent experiments, we observed that the level of phosphorylation was about 1.5-fold more
important using extracts from Vero than ND7 cells. Furthermore, the
level of phosphorylation was significantly reduced using 1 mM DRB, suggesting the involvement of CKI and/or CKII in
both cell types (Fig. 5A). In vitro kinase assays
using cellular protein extracts from Vero and ND7 cells were also
carried out with the wild-type GST-IE63 and GST-IE63-10M proteins as
substrates (Fig. 5B). We observed that the mutation of the
10 putative IE63 phosphorylation sites had an impact on the
phosphorylation rate of the protein but did not lead to its complete
depletion. Again, this observation suggests that cellular kinases might
use other phosphorylation sites on IE63 than the one targeted by our
study. We also determined the casein kinase activity on wild-type
GST-IE63 or GST-IE63-10M in both cell types (Fig. 5C). For
this, an in vitro kinase assay was carried out as described
above, and the phosphorylation rate obtained for each sample was
quantified by phosphorimaging analysis. All values obtained were then
plotted versus a reference activity curve, established by
measuring the phosphorylation rate of wild-type GST-IE63 protein, using
decreasing concentrations of CKII. The casein kinase activity
determined in Vero cells was 0.66 unit/µg total protein extract and
0.42 unit/µg total protein extract from ND7 cells using wild-type
GST-IE63 as substrate. These data clearly demonstrate that the
phosphorylation rate of wild-type IE63 is somewhat less important using
protein extracts from ND7 than from Vero cells. The casein kinase
activity measured for the GST-63-10M protein was about 0.26 unit/µg
total protein extracts from Vero cells and 0.21 unit/µg total protein
extracts from ND7 cells, indicating that the mutation of the 10 potential phosphorylations have an important impact on the
phosphorylation rate of IE63 but did not prevent it to be
phosphorylated by cellular kinases. Results are also given for GST
alone as negative control.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 5.
Comparison of the IE63 phosphorylation rate
using either Vero or ND7 cellular protein extracts. A,
wild-type GST-IE63 coupled with Sepharose was incubated with 30 µg of
total protein extracts from Vero or ND7 cells previously dialyzed and
[ 32P]ATP and in the presence (+) or absence ( ) of
1 mM DRB. PhosphorImaging analysis of the autoradiography
(KA) and the Coomassie Blue-stained (CB) SDS-PAGE
gel allowed us to determine the relative percentage of phosphorylation
for each samples. B, in vitro phosphorylation of
wild-type GST-IE63 or GST-IE63-10M using total protein extracts from
either Vero or ND7 cells. The kinase assay and the analysis of the
results were performed as described above. C, the CK-like
activity present in Vero and ND7 protein extracts was determined either
on wild-type GST-IE63 protein, GST-IE63-10M, or GST. Results are given
in units of CK activity per µg of cellular protein extracts.
|
|
IE63 Phosphorylation Influences Its Cellular Localization--
We
decided to investigate the importance of IE63 phosphorylation on its
localization. Plasmids encoding the wild-type and mutated proteins were
transfected in both Vero and ND7 cells. Their cellular localization was
observed by immunostaining analysis using either monoclonal or
polyclonal antibodies directed against IE63. Quantitative analysis was
carried out, and the cellular localization of the proteins in both cell
lines was determined, based on at least three independent experiments
(Table II). Previous reports (20)
revealed that during VZV lytic infection, IE63 is mainly localized in
the nucleus of infected cells. When transfected in both Vero and ND7
cells, a prevalent nuclear localization of the protein with a slight
cytoplasmic localization was observed (Fig.
6A). Indeed, IE63 was present
in the nucleus of more than 90% of transfected cells. A positive
control for the cytoplasmic localization of IE63 was constructed. Based
on a previous report (24), we removed the carboxyl-terminal region of
IE63 (amino acids 210-278) necessary for the nuclear localization of
the protein, in order to generate pcDNA63-
K. We also observed an
almost complete cytoplasmic localization of this truncated protein when
transfected either in Vero or in ND7 cells (Fig. 6B). About
82% of Vero cells expressing the protein exhibited a cytoplasmic
staining, whereas in ND7 cells, almost all positive cells were stained
in the cytoplasm (Table II). This localization of the protein could
possibly be explained by the removal of a KRRR region coding for a
putative nuclear localization signal (amino acids 260-264). It is also important to note the loss of two putative phosphorylation sites (Ser-224 and Thr-244) for PKC/Cdc2 and CKI, respectively, in IE63
K. We decided then to remove solely the 260KRRR region coding
for the putative nuclear localization signal (pcDNA63-
NLS). When
transfected into Vero cells, we observed a major, but not exclusive,
localization of this protein in the cytoplasm (Fig. 6C);
60% of Vero cells exhibited a cytoplasmic accumulation of IE63,
whereas in the other 40%, the protein was evenly distributed between
nucleus and cytoplasm (Table II). In ND7, up to 83% of transfected
cells was positively stained in the cytoplasm. These results
demonstrate that this 260KRRR region is a functional
nuclear localization signal for the IE63 protein and is important for
its nuclear localization in both cell lines. Meanwhile, as the
IE63-
NLS protein was not exclusively confined to the cytoplasm of
Vero cells, we might postulate that other surrounding residues of IE63
could participate to this process in that cell type.
View this table:
[in this window]
[in a new window]
|
Table II
Analysis of the intracellular localization of IE63 after transfection
of Vero or ND7 cells with the several constructionconstructions
Vero or ND7 cells were transfected with 1 µg of plasmids. 40 hours
post-transfection, immunofluorescent staining was carried out. Positive
cells were counted and classified according to the IE63 cellular
localization: N > C for a major nuclear staining, N = C for
an equal distribution of the proteins between nucleus and cytoplasm,
and N < C for a major cytoplasmic staining. Average percentages
are the results of at least three independent experiments. From these
experiments, the relative error was estimated at 15-20%.
|
|

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 6.
Intracellular localization of wild-type IE63
or mutated in Vero and ND7 cells. Vero and ND7 cells were
transfected with 1 µg of plasmid expressing wild-type IE63
(A), IE63- K (B), IE63- NLS (C),
IE63-5M (D), and IE63-10M (E). 40 h
post-transfection, immunostaining analysis was carried out using a
monoclonal antibody (9A12) directed against IE63 (A,
D, and E). Polyclonal antibodies were also used
(B and C), as the monoclonal antibody did not
recognize the truncated IE63 proteins. Secondary antibodies used were
coupled with FITC.
|
|
No major impact on IE63 localization was observed when the first three
putative phosphorylation sites for CKII (Ser-150, Ser-165, and Thr-171
into pcDNA63-1M, pcDNA63-2M, pcDNA63-3M, and
pcDNA63-4M) were removed (data not shown). However, when Vero cells
were transfected with pcDNA-5M, where the five putative
phosphorylation sites for CKII (Ser-150, Ser-165, Thr-171, Ser-181, and
Ser-186) were removed, a slight delocalization of the protein from the
nucleus to the cytoplasm was observed in Vero cells (Fig.
6D). Indeed, less than 60% of Vero cells was stained
predominantly in the nucleus, whereas about 23% of cells exhibited a
uniform localization of IE63 between both cellular compartments, and
17% were marked mainly in the cytoplasm (Table II). In contrast, the
IE63-5M protein was mainly localized in the nucleus of ND7 cells as the
wild-type protein (Fig. 6D).
When mutations for the CKI and PKC/Cdc2 putative phosphorylation sites
were also included (pcDNA63-10M), we observed an increasing delocalization of the IE63 protein from the nucleus to the cytoplasm of
Vero cells (Fig. 6E). We also observed a striking
accumulation of the protein at the nuclear envelope, just as if the
protein had been excluded from the nucleus and was concentrating in the perinuclear space. In this case, more than 65% of the positive Vero
cells exhibited a predominant cytoplasmic localization (Table II).
Again, no major impact of these mutations was observed on the
localization of the protein when transfected in ND7 cells (Fig.
6E). These results indicated an important role of the
phosphorylation event in the cellular localization of the IE63 protein
in Vero cells. In the neuronal cell line we tested, however,
phosphorylation of these residues did not play an important role for
the correct protein localization.
Phosphorylation Influences IE63 Regulating
Properties--
Regulatory properties of IE63 are still unclear at
this time. It was shown previously (22) that this protein can either up-regulate the thymidine kinase gene or down-regulate the
ORF62 gene, but these results were questioned by a later
report suggesting a limited regulatory activity of IE63 on VZV gene
expression (23). In this context, we decided to investigate in more
detail the activity of IE63 and to observe the impact of
phosphorylation events on gene regulation. The regulatory properties of
the wild-type or mutated IE63 protein were assayed on the basal
expression of the VZV DNA polymerase gene promoter (pPol). This
promoter is an accurate tool for repression studies, as it exhibits a
rather important constitutive activity. For this, transient
transfections were carried out using a luciferase reporter gene under
the control of the VZV pPol (pPol-luc). Vero and ND7 cells were
transfected with 1 µg of this plasmid and with increasing
concentrations of wild-type or mutated pcDNA63. Each independent
condition tested was carried out using the same equimolar ratio of
promoters. Results were expressed in percentage of stimulation with
respect to the basal activity obtained with the pPol-luc alone (=
100%). First, the efficient expression of wild-type or mutated IE63
proteins was verified by Western blotting analysis (Fig.
7). In Vero or in ND7 cells, we observed
a significant decrease of the basal luciferase activity when increasing
concentrations of wild-type pcDNA-63 were added (Fig.
8A). The observed repression
was about 70% in both cell types at 6 µg of wild-type pcDNA63.
In order to validate our reporter system, we tested the ability of IE63 to repress another VZV promoter. For this, we used the thymidine kinase
promoter controlling the expression of the chloramphenicol acetyltransferase (CAT) reporter gene (Fig. 8B). We observed
in this system that IE63 is also able, in both cell lines, to repress the basal activity of the thymidine kinase promoter to a similar level
to what was observed with the VZV DNA polymerase promoter. All
following experiments were then conducted using this pPol-luc reporter
system. It is also important to note that a construct, where the
wild-type IE63 gene had been cloned in the reverse
orientation, was used as a negative control (pcDNA63inv). With this
plasmid transfected in identical conditions, as described above, no
repression on the basal activity of the VZV DNA polymerase promoter was
observed in both cell lines (Fig. 8C), demonstrating that
the repressive activity of IE63 was due to the expression of a
correctly expressed IE63.

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 7.
Control of the expression of wild-type and
mutated IE63 in transfected cells. Protein extracts from ND7 cells
previously transfected with 1 µg of pPol-luc plasmid and increasing
concentrations of wild-type pcDNA63 (A), pcDNA63-10M
(B), pcDNA63- NLS (C) or pcDNA63- K
(D) were loaded on a 10% SDS-PAGE gel. After migration and
transfer, IE63 proteins were detected using either monoclonal
(A and B) or polyclonal (C and
D) antibodies. Secondary antibodies used were coupled to
peroxidase.
|
|

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of wild-type or mutated IE63 on the
VZV promoter basal expression. Vero and ND7 cells were transfected
with 1 µg of pPol-luc (A and C-F) or with 1 µg of pTK-CAT (B). Increasing concentrations of plasmids
expressing wild-type IE63 (A and B), IE63 inv
(C), IE63-10M (D), IE63- K (E), and
IE63- NLS (F) were added. Forty hours post-transfection,
cells were harvested, and the reporter gene activity was measured.
Results are presented in percentage of stimulation with
respect to the basal expression of the promoter (= 100%).
|
|
When this experiment was performed using the IE63 protein mutated on
the 10 potential phosphorylation sites (IE63-10M), no significant
repression of the luciferase activity was observed in ND7 cells,
whereas in Vero cells, this activity was greatly reduced (Fig.
8D). These results suggest the importance of the phosphorylation events for a complete and functional activity of IE63.
This loss of activity seemed to be dependent on the phosphorylation mechanism and was not due to a change in the cellular localization in
Vero cells, because experiments carried out with the pcDNA-63
NLS (Fig. 8E) revealed that IE63-
NLS, mainly localized in the
cytoplasm, was still able to repress the basal activity of the
promoter. The repression property observed with the IE63-
NLS protein
was similar to that observed with the wild-type protein in both cell types, indicating that the 260KRRR region was not required
for the activity of IE63 on this promoter. These results also suggest
that IE63 is able to exert its activity by two independent ways,
through a transcriptional or a post-transcriptional mechanism in the
nucleus and/or a post-transcriptional mechanism in the cytoplasm. This
phosphorylation-dependent regulation mechanism is not cell
type-dependent because it was observed in both ND7 and Vero
cells. Interestingly, we also observed that IE63, deleted from its
carboxyl-terminal region (pcDNA-63
K), was still able to act as
a repressor on the luciferase reporter gene when transfected in Vero
cells but not in ND7 cells (Fig. 8F). These data suggest
that, in ND7 cells, the repressive activity of IE63 is dependent on the
carboxyl-terminal region (amino acids 210-278). This region contains a
NLS and also two putative phosphorylation sites for PKC/Cdc2 or CKI. As
experiments carried out with pcDNA63-
NLS showed that the NLS was
not required for the activity of the protein, we might suspect that the
presence of these two putative phosphorylation sites are important for
the repressive activity of IE63 in ND7 cells but not crucial in Vero cells.
We also decided to evaluate the regulatory properties of wild-type or
mutated IE63 when the expression of the pPol-luc promoter was
stimulated by IE62, a VZV-encoded transcription factor. Indeed, it has
been shown previously that IE62 was able to activate the VZV DNA
polymerase promoter when transfected in cells (34). For this, Vero and
ND7 cells were transfected with 1 µg of pPol-luc. Stimulation was
achieved using 0.5 µg of pcDNA-IE62, and increasing concentrations of wild-type pcDNA63 or pcDNA63-10M were added. Results were presented in percentage of stimulation with respect to the
stimulation obtained with 0.5 µg of pcDNA62. As expected, IE62
was able to stimulate the expression of the reporter gene up to 20-fold
in Vero cells and about 10-fold in ND7 cells (data not shown). The
difference in the level of pPol-luc stimulation between both cell lines
could be explained by the fact that the level of basal expression of
the VZV DNA polymerase promoter was higher in ND7 than in Vero cells.
This stimulation was greatly reduced when increasing concentrations of
wild-type IE63 were added, in both cell lines (Fig.
9A). Indeed, using 6 µg of
wild-type pcDNA63, the stimulation of the promoter was about 30%
that observed without IE63 in both cell types. Again, when the 10 putative phosphorylation sites of IE63 had been mutated, no repressive
activity of the protein was observed in ND7 cells, whereas in Vero
cells, this IE63-10M protein still exhibited some repressive properties
(Fig. 9B).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 9.
Effect of wild-type or mutated IE63 on the
expression of the VZV DNA polymerase promoter stimulated by IE62.
Vero and ND7 cells were transfected with 1 µg of pPol-luc and 0.5 µg of pcDNA-IE62. Increasing concentrations of plasmid encoding
wild-type IE63 (A) or IE63-10M (B) were added.
40 h post-transfection, cells were harvested, and the luciferase
activity was measured. Results are presented as a percentage of
stimulation with respect to the stimulation obtained with 0.5 µg of
pcDNA62 (= 100%).
|
|
 |
DISCUSSION |
The viral tegument is an amorphous structure located between the
capsid and the external envelope of herpesviruses. Four different proteins, ORF10, IE4, IE62 and IE63, have been identified within the
VZV tegument (35). They have all been described previously as
regulatory proteins; ORF10, the homologue of HSV-1 VP16 protein, is
able to transactivate the VZV IE62 promoter (36), whereas IE4 and IE62 are phosphoproteins known for their ability to stimulate the expression of all three classes of VZV genes (IE, E, and L) (4-8,
28). The activity of IE63 is not so well defined. This tegument protein
possesses regulatory properties on the viral gene expression as shown
previously (22), but these results were disputed (23).
The first part of this report was devoted to the analysis of the
important phosphorylation sites of IE63. We showed that cellular kinases from both Vero and ND7 cells were able to phosphorylate this
protein and that the phosphorylation rate of IE63 was higher in the
permissive and non-neuronal cell line (Vero), compared with the
neuronal but not permissive ND7 cells. Immunoprecipitation experiments
and the use of a CKI and CKII inhibitor (DRB) in an in vitro
kinase assay allowed us to conclude that those cellular kinases were
implicated in IE63 phosphorylation. CKI and CKII are ubiquitous
proteins involved in many cellular events; CKII is known to be
implicated in various biological processes such as signal transduction,
cell cycle, apoptosis, and cell transformation, and it can
phosphorylate more than 160 proteins including many viral proteins
(37). CKI was also described as a pleiotropic kinase with a large
number of substrates (38). Phosphorylation of IE63 in Mewo cells, or
using recombinant CKII, was described previously (24), and potential
phosphorylation sites were predicted in the carboxyl-terminal region of
the protein (between residues 142 and 278). A site-directed mutagenesis
strategy allowed us to show that phosphorylation of IE63 was not
restricted to the five serine or threonine residues targeted by CKII in
this region (Ser-150, Ser-165, Thr-171, Ser-181, and Ser-186). Indeed,
the IE63-5M protein, where all these potential CKII sites are mutated into alanine residues, may still be phosphorylated using recombinant CKII. These results suggest that CKII might also use target sites located elsewhere in the protein. Analysis of the amino acid sequence of the protein revealed the presence of two other putative
phosphorylation sites for CKII in the amino-terminal (Thr-8) and in the
central (Thr-124) parts of the protein. Using two other prediction
programs (NetPhos 2.0 (39) and Scansite (40)) Ser-197 can also be
identified as a residue with a high probability of being
phosphorylated. According to the scansite program Ser-197 might be a
potential target for CKII. The relevance and the implication of these
sites in the phosphorylation of IE63 remain to be elucidated. We also observed a slightly higher CKI phosphorylation rate of IE63-5M in
comparison with the wild-type protein. We suspect that mutations introduced in this mutant might modify the accessibility and/or the
affinity of CKI for its target sites.
Four potential sites for CKI (Ser-173, Ser-185, Thr-201, and Thr-244)
and 1 site for PKC/Cdc2 (Ser-224) are present in the carboxyl-terminal
region of IE63. The impact of their mutation, in combination with those
for CKII, was investigated (IE63-10M). These results indicated that CKI
was implicated in the phosphorylation process of IE63. Indeed, we
showed that wild-type IE63 may be phosphorylated in vitro
using recombinant CKI and that the mutation of the four phosphorylation
sites largely abrogated its phosphorylation by CKI. Netphos and
Scansite analyses also revealed the presence of two other sites of high
probability for being phosphorylated by CKI, Ser-15 and Ser-203. These
residues might be responsible for the slight phosphorylation remaining
in the IE63-10M mutated protein. Interestingly, we also noticed a lower
CKII phosphorylation rate of the IE63-10M protein in comparison to what
was observed with the IE63-5M. We postulate that the last mutations
introduced in the IE63-10M protein (and especially the mutation of the
residue 201) could have modified Ser-197 accessibility to CKII.
Kinase assays performed using cellular protein extracts and measure of
the casein kinase activity revealed an important decrease (60-70%
using Vero and ND7 protein extracts, respectively) of the
phosphorylation rate of IE63-10M in comparison with the wild-type protein. This observation has been made regardless of the nature of the
cell type, even if the phosphorylation rate of IE63 was more important
using protein extracts from Vero than from ND7 cells. These results
obtained with the neuronal and non-neuronal cellular models suggested
that members of the casein kinase family are implicated in the
phosphorylation of IE63.
Phosphorylation and dephosphorylation events are implicated in many
cellular regulatory activities such as cell cycle, signal transduction,
or gene expression (41-43). Many transcription factors are common
targets for cellular kinases and are regulated by phosphorylation mechanisms (41, 42). Indeed, one of the strategies developed by cells
to regulate the expression of cellular genes is the control of
transcription factors localization and their shuttling through the
nucleus. For example, phosphorylation of IE62 by the viral ORF66 kinase
led to its delocalization from the nucleus to the cytoplasm, impairing
its transactivation properties (44). In this context, we investigate
the impact of phosphorylation event on the cellular localization of
IE63. The use of two different cell lines allowed us to compare the
behavior of IE63 in a non-neuronal cell line permissive to VZV (Vero)
and in neuronal ND7 cells, previously shown to be of low permissivity
to HSV-1 infection (26). We demonstrated here that VZV does not
replicate in this cell type. The wild-type IE63 protein exhibits a
major nuclear localization in Vero- and ND7-transfected cells, as
observed previously (20) in infection studies. The removal of the four
amino acids located between residues 260 and 264 (KRRR) led to a
predominant cytoplasmic localization of the protein in both cell lines,
suggesting that this short basic sequence acts as an effective, but not
exclusive, nuclear localization signal for IE63. The removal of a large
part of the carboxyl-terminal region of the protein (IE63-
K) induced a cytoplasmic delocalization of the protein when transfected in Vero
and in ND7 cells, confirming the observations of others in Mewo cells
(24). The mutation of the five potential phosphorylation sites for CKII
located in the carboxyl-terminal region of IE63 led to a slight
delocalization of the protein from the nucleus to the cytoplasm of Vero
cells. Experiments carried out with mutants IE63-1M, IE63-2M, IE63-3M,
and IE63-4M, where only some of the CKII phosphorylation sites were
mutated, did not shed light on determining the CKII site responsible
for this slight delocalization. Furthermore, the mutation of all CKI,
CKII, and PKC/Cdc2 phosphorylation sites located in this area
(IE63-10M) considerably alters the localization of IE63 in Vero cells,
as more than 65% of them exhibited a major cytoplasmic staining. In
this case, we also observed a striking localization of the protein at
the nuclear membrane, suggesting that the absence of phosphorylation
impaired its transport into the nucleus. Results obtained with several
intermediate constructs, such as IE63-6M, IE63-7M, IE63-8M, and
IE63-9M, did not allow us to identify a key site in the process (data
not shown). Our observations suggest that the correct import of IE63
into the nucleus requires a complete phosphorylation of the
carboxyl-terminal region of the protein, rather than the
phosphorylation of one or two particular sites. However, it should be
pointed out that Ser-224 could also be considered as a potential target
site for p34cdc2, a member of the cyclin-dependent
serine/threonine kinase family involved in the G2/M
transition of the cell cycle (45). It has been shown previously that,
during HSV-1 infection, this cellular kinase is required for the
expression of a subset of late viral proteins and that its own
expression is induced by UL13 and ICP22, the latter being the HSV-1
homologue of IE63 (46). Furthermore, several reports (46-49) also
indicated that Cdc2 could modulate the cellular localization and the
function of several transcription factors. In this context, it would be
interesting to define the potential role that this kinase could play on
the localization and/or activity of IE63. An interesting observation
was also made when the cellular localization of IE63 mutated in some of
its phosphorylation sites was investigated in ND7 cells. Indeed, in this neuronal cell line, no impact of the mutations of the
phosphorylation sites was observed; the IE63-5M and IE63-10M proteins
exhibited a nuclear localization like the wild-type protein, and after
deletion of its NLS, the protein remains in the cytoplasm of
transfected cells. These results indicate that in permissive cells
(Vero), phosphorylation of the IE63 protein is important for its
accurate localization, whereas in cells that do not support VZV
infection (ND7), the phosphorylation rate of IE63 does not seem to be a critical factor for its subcellular localization. This suggests that,
depending on the cell type, IE63 might use different transport mechanisms that could be more or less sensitive to its phosphorylation status. Numerous reports indicate that
phosphorylation-dependent mechanisms may regulate the
subcellular localization of proteins such as those containing a CcN
motif, a short region containing phosphorylation sites for CKII and
Cdc2 in the vicinity of a nuclear localization signal (50-54).
To understand the relevance of the
phosphorylation-dependent localization of IE63, we
developed an activity assay with the wild-type protein and then
examined the behavior of the mutated proteins in this context. Because
the trans-repressive properties of IE63 on IE promoters have been
questioned (23), we investigated the activity of IE63 on the regulation
of the gene encoding the DNA polymerase, a putative early protein
(ORF28). Results indicated that the wild-type IE63 protein was able, in
a dose-dependent way, to down-regulate the expression of
the luciferase reporter gene driven by this promoter (pPol) in both
cell lines tested. This repressive activity was clearly observed either
in the basal activity of the pPol or after its stimulation by IE62.
This down-regulating property might reflect an important role played by
IE63 in the infectious cycle. An important feature of IE63 was observed
when experiments were carried out with the 63
NLS protein. Indeed, despite its cytoplasmic localization, this protein was still capable of
repressing the basal expression of the pPol. This property was
established in neuronal and in non-neuronal cells with an efficiency
similar to the wild-type protein. IE63 thus acts as a repressor either
in the nucleus or in the cytoplasm of transfected cells, and this viral
protein could exert its activity by two independent ways, through
transcriptional and/or post-transcriptional mechanisms. Experiments
carried out with the IE63-10M protein indicated that the
phosphorylation status of IE63 is important for its activity. Indeed,
in neuronal cells we observed a complete loss of the pPol repression
when phosphorylation sites of the protein were mutated. These
observations were made when pPol was stimulated by IE62 and on its
basal activity. In Vero cells, the repression property of IE63 on the
basal expression of the promoter was also slightly reduced. Hence, the
phosphorylation status of IE63, rather than its cellular localization,
is critical for the fulfillment of its repressive activity, and casein
kinases are involved in the regulatory process. Several reports (37,
55, 56) indicate that members of the CK family possess regulatory properties and are involved in the control of cellular or viral gene expression.
Taken together, these results indicate that in the models studied,
cellular CKI and CKII are important for the correct nuclear localization of IE63 and for its repressive properties in a cell type-dependent way. Furthermore, we showed that IE63 exerts
its repressive properties in the nucleus as well as in the cytoplasm of
transfected cell, suggesting its implication in transcriptional and/or
post-transcriptional mechanism(s). In order to determine the biological
relevance of our observations and to evaluate them in an infectious
context, we intend to develop a VZV recombinant virus carrying
mutations in the phosphorylation sites of IE63 genes. The
replication of this recombinant virus will be tested in cultured cells,
and its infectivity and its ability to establish latency in dorsal root
ganglias will be addressed in our rat model. Recent studies (25)
indicated that ORF47, one of the VZV-encoded kinase, is able to use
IE63 as substrate in vitro. This Ser/Thr kinase has often
been compared with CKII and is not essential for viral replication in
cultured cells (57-60). Meanwhile, a study developed in a SCID-hu mice
model indicated that ORF47 is required for viral growth in human T
cells and skin (61). Although this suggested that in the differentiated
cells studied endogenous CKII is unable to compensate the lack of
ORF47, it will be necessary to clarify the ability of ORF47 to
phosphorylate in vivo IE63 and to estimate the impact on its
localization and activity before inferring a role for cellular kinases
in the infection process.
 |
ACKNOWLEDGEMENT |
We thank N. Renotte for technical assistance.
 |
FOOTNOTES |
*
This work was supported in part by a grant from the Belgian
National Fund for Scientific Research.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Supported by Televie.
§
Supported by Fonds pour la Recherche en Industrie et Agriculture.
¶
Research director at the Belgian National Fund for Scientific
Research. To whom correspondence should be addressed: Laboratory of
Virology and Immunology, Institute of Pathology B23, University of
Liège, B-4000 Liège, Belgium. Tel.: 32-4-366-2442; Fax:
32-4-366-9933; E-mail: jpiette@ulg.ac.be.
Published, JBC Papers in Press, March 23, 2002, DOI 10.1074/jbc.M111872200
 |
ABBREVIATIONS |
The abbreviations used are:
VZV, varicella-zoster virus;
HSV-1, herpes simplex virus type 1;
IE, immediate early;
E, early;
L, late;
ORF, open reading frame;
CKI, casein kinase I;
CKII, casein kinase II;
PKC, protein kinase C;
NLS, nuclear localization signal;
DRB, 5,6-Dichloro-1-
-D-ribofuranosylbenzimidazole;
CAT, chloramphenicol acetyltransferase;
FITC, fluorescein isothiocyanate;
wt, wild type;
PBS, phosphate-buffered saline;
GST, glutathione
S-transferase.
 |
REFERENCES |
| 1.
|
Flisser, A.,
and Tapia-Conyer, R.
(1999)
Contrib. Microbiol.
3,
76-85[Medline]
[Order article via Infotrieve]
|
| 2.
|
Lungu, O.,
and Annunziato, P. W.
(1999)
Contrib. Microbiol.
3,
61-75[Medline]
[Order article via Infotrieve]
|
| 3.
|
Honess, R. W.,
and Roizman, B.
(1974)
J. Virol.
14,
8-19[Abstract/Free Full Text]
|
| 4.
|
Inchaupse, G.,
Nagpal, S.,
and Ostrove, J. M.
(1989)
Virology
173,
700-709[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Perera, L. P.,
Mosca, J. D.,
Sadeghi-Zadeh, M.,
Ruyechan, W. T.,
and Hay, J.
(1992)
Virology
191,
346-354[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Kinchington, P.,
Hougland, J. K.,
Arvin, A. M.,
Ruyechan, W. T.,
and Hay, J.
(1992)
J. Virol.
66,
359-366[Abstract/Free Full Text]
|
| 7.
|
Perera, L. P.,
Mosca, J. D.,
Ruyechan, W. T.,
and Hay, J.
(1992)
J. Virol.
66,
5298-5304[Abstract/Free Full Text]
|
| 8.
|
Baudoux, L.,
Defechereux, P.,
Schoonbroodt, S.,
Merville, M. P.,
Rentier, B.,
and Piette, J.
(1995)
Nucleic Acids Res.
8,
1341-1349
|
| 9.
|
Croen, K. D.,
Ostrove, J. M.,
Dragovic, L. J.,
and Straus, S. E.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
9773-9777[Abstract/Free Full Text]
|
| 10.
|
Meier, J. L.,
Holman, R. P.,
Croen, K. D.,
Smialek, J. E.,
and Straus, S. E.
(1993)
Virology
193,
193-200[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Vafai, A.,
Wellish, M.,
and Gilden, D. H.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
2767-2770[Abstract/Free Full Text]
|
| 12.
|
Cohrs, R. J.,
Srock, K.,
Barbour, M. B.,
Owens, G.,
Mahalingam, R.,
Devlin, M. E.,
Wellish, M.,
and Gilden, D. H.
(1994)
J. Virol.
68,
7900-7908[Abstract/Free Full Text]
|
| 13.
|
Cohrs, R. J.,
Barbour, M. B.,
Mahalingam, R.,
Wellish, M.,
and Gilden, D. H.
(1995)
J. Virol.
69,
2674-2678[Abstract]
|
| 14.
|
Cohrs, R. J.,
Barbour, M.,
and Gilden, D. H.
(1996)
J. Virol.
70,
2789-2796[Abstract]
|
| 15.
|
Kennedy, P. G.,
Grinfeld, E.,
and Gow, J. W.
(1999)
Virology
258,
451-454[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Mahalingam, R.,
Wellish, M.,
Cohrs, R.,
Debrus, S.,
Piette, J.,
Rentier, B.,
and Gilden, D. H.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
2122-2124[Abstract/Free Full Text]
|
| 17.
|
Lungu, O.,
Panagiotidis, C. A.,
Annunziato, P. W.,
Gershon, A. A.,
and Silverstein, S. J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7080-7085[Abstract/Free Full Text]
|
| 18.
|
Kennedy, P.,
Grinfeld, E.,
Bontems, S.,
and Sadzot-Delvaux, C.
(2001)
Virology
289,
218-223[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Spengler, M.,
Niesen, N.,
Grose, C.,
Ruyechan, W. T.,
and Hay, J.
(2001)
Arch. Virol.
17 (suppl.),
71-79
|
| 20.
|
Debrus, S.,
Sadzot-Delvaux, C.,
Nikkels, A. F.,
Piette, J.,
and Rentier, B.
(1995)
J. Virol.
69,
3240-3245[Abstract]
|
| 21.
|
Sommer, M. H.,
Zagha, E.,
Serrano, O. K., Ku, C. C.,
Zerboni, L.,
Baiker, A.,
Santos, R.,
Spengler, M.,
Lynch, J.,
Grose, C.,
Ruyechan, W.,
Hay, J.,
and Arvin, A. M.
(2001)
J. Virol.
17,
8224-8239
|
| 22.
|
Jackers, P.,
Defechereux, P.,
Baudoux, L.,
Lambert, C.,
Massaer, M.,
Merville-Louis, M. P.,
Rentier, B.,
and Piette, J.
(1992)
J. Virol.
66,
3899-3903[Abstract/Free Full Text]
|
| 23.
|
Kost, R. G.,
Kupinsky, H.,
and Straus, S. E.
(1995)
Virology
209,
218-224[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Stevenson, D.,
Xue, M.,
Hay, J.,
and |